Hansa Biopharma AB (publ) (0RC7.IL)

38.76 +0.06 (+0.16%) At close: 05:33PM BST

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 162

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Søren Tulstrup M.Sc	Pres & CEO	15.26M	N/A	1965
Mr. Donato Spota	CFO & Sr. VP	N/A	N/A	1971
Dr. Christian Kjellman	Sr. VP, Chief Scientific Officer & COO	N/A	N/A	1967
Ms. Eva-Maria Joed	VP of Fin. & Admin.	N/A	N/A	1969
Mr. Klaus Sindahl	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Anne Säfström Lanner	Sr. VP & Chief HR Officer	N/A	N/A	1969
Mr. Emanuel Björne	VP & Head of Bus. Devel.	N/A	N/A	1973
Dr. Lena Winstedt	Head of Science	N/A	N/A	1969
Ms. Vincenza Nigro M.B.A.	VP & Head of Medical Affairs	N/A	N/A	N/A
Dr. Achim Kaufhold M.D., Ph.D.	Sr. VP & Chief Medical Officer	N/A	N/A	1958

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Corporate Governance

Hansa Biopharma AB (publ)’s ISS Governance QualityScore as of October 1, 2023 is 2. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.